Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00
Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective upped by Canaccord Genuity Group from $9.00 to $11.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock. A number of other research analysts have also recently issued reports on TSHA. Citigroup reiterated an “outperform” rating on […]
Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective upped by Canaccord Genuity Group from $9.00 to $11.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock. A number of other research analysts have also recently issued reports on TSHA. Citigroup reiterated an “outperform” rating on […]
